Literature DB >> 10806352

Characterization of the human EPLIN (Epithelial Protein Lost in Neoplasm) gene reveals distinct promoters for the two EPLIN isoforms.

S Chen1, R S Maul, H R Kim, D D Chang.   

Abstract

EPLIN is a novel LIM domain protein that co-localizes to the actin stress fibers and focal adhesion plaques. We previously have demonstrated that two isoforms, the 600aa EPLIN-alpha and the 759aa EPLIN-beta, are generated from a single gene. In the majority of human breast and prostate cancer cell lines, the expression of EPLIN-alpha is significantly reduced, while the expression of EPLIN-beta is either up-regulated or unchanged. To understand the basis of this differential regulation, we have determined the organization of the human EPLIN gene. The human EPLIN100kb and consists of 11 exons. The EPLIN-beta mRNA requires all 11 exons, while the EPLIN-alpha mRNA requires Exons 4-11. The transcriptional start sites of EPLIN-alpha were mapped within the third intron by 5' RACE and S1 nuclease protection. Similarly, the 5' ends of EPLIN-beta were mapped upstream of Exon 1. The DNA sequences flanking the EPLIN-alpha or EPLIN-beta transcriptional start sites were capable of stimulating the expression of promoter reporter constructs. Interestingly, the endogenous transcription of EPLIN-alpha, but not EPLIN-beta, could be stimulated by serum, indicating that the expression of two EPLIN isoforms can be independently regulated. A consensus serum response element was present within 100bp upstream of the transcriptional start sites of EPLIN-alpha. The activity of 0.7kb EPLIN-alpha promoter reporter construct could be enhanced by activated RhoA, indicating that this serum response element is functional.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10806352     DOI: 10.1016/s0378-1119(00)00144-x

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  14 in total

1.  Epithelial protein lost in neoplasm (EPLIN) interacts with α-catenin and actin filaments in endothelial cells and stabilizes vascular capillary network in vitro.

Authors:  Adeline Chervin-Pétinot; Marie Courçon; Sébastien Almagro; Alice Nicolas; Alexei Grichine; Didier Grunwald; Marie-Hélène Prandini; Philippe Huber; Danielle Gulino-Debrac
Journal:  J Biol Chem       Date:  2011-12-22       Impact factor: 5.157

2.  Human phosphatase CDC14A regulates actin organization through dephosphorylation of epithelial protein lost in neoplasm.

Authors:  Nan-Peng Chen; Borhan Uddin; Robert Hardt; Wen Ding; Marko Panic; Ilaria Lucibello; Patricia Kammerer; Thomas Ruppert; Elmar Schiebel
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-02       Impact factor: 11.205

3.  Inhibition of anchorage-independent growth of transformed NIH3T3 cells by epithelial protein lost in neoplasm (EPLIN) requires localization of EPLIN to actin cytoskeleton.

Authors:  Yuhong Song; Raymond S Maul; C Sachi Gerbin; David D Chang
Journal:  Mol Biol Cell       Date:  2002-04       Impact factor: 4.138

4.  EPLINβ Is Involved in the Assembly of Cadherin-catenin Complexes in Osteoblasts and Affects Bone Formation.

Authors:  Shihoko Miyazaki; Taro Funamoto; Tomohisa Sekimoto; Syuji Kurogi; Tomomi Ohta; Takuya Nagai; Takuya Tajima; Mai Imasaka; Kumiko Yoshinobu; Kimi Araki; Masatake Araki; Narantsog Choijookhuu; Yoshitaka Hishikawa; Etsuo Chosa
Journal:  Acta Histochem Cytochem       Date:  2022-06-25       Impact factor: 1.857

5.  Epithelial Protein Lost in Neoplasm alpha (Eplin-alpha) is transcriptionally regulated by G-actin and MAL/MRTF coactivators.

Authors:  Laura Leitner; Dmitry Shaposhnikov; Arnaud Descot; Reinhard Hoffmann; Guido Posern
Journal:  Mol Cancer       Date:  2010-03-17       Impact factor: 27.401

6.  EPLIN mediates linkage of the cadherin catenin complex to F-actin and stabilizes the circumferential actin belt.

Authors:  Kentaro Abe; Masatoshi Takeichi
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-18       Impact factor: 11.205

7.  Epidermal growth factor promotes protein degradation of epithelial protein lost in neoplasm (EPLIN), a putative metastasis suppressor, during epithelial-mesenchymal transition.

Authors:  Shumin Zhang; Xu Wang; Shareen Iqbal; Yanru Wang; Adeboye O Osunkoya; Zhengjia Chen; Zhuo Chen; Dong M Shin; Hongwei Yuan; Yongqiang A Wang; Haiyen E Zhau; Leland W K Chung; Chad Ritenour; Omer Kucuk; Daqing Wu
Journal:  J Biol Chem       Date:  2012-11-27       Impact factor: 5.157

8.  EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis.

Authors:  S Zhang; X Wang; A O Osunkoya; S Iqbal; Y Wang; Z Chen; S Müller; Z Chen; S Josson; I M Coleman; P S Nelson; Y A Wang; R Wang; D M Shin; F F Marshall; O Kucuk; L W K Chung; H E Zhau; D Wu
Journal:  Oncogene       Date:  2011-05-30       Impact factor: 9.867

Review 9.  EPLIN: a fundamental actin regulator in cancer metastasis?

Authors:  Ross J Collins; Wen G Jiang; Rachel Hargest; Malcolm D Mason; Andrew J Sanders
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

10.  Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome.

Authors:  Wen G Jiang; Tracey A Martin; Jonathan M Lewis-Russell; Anthony Douglas-Jones; Lin Ye; Robert E Mansel
Journal:  Mol Cancer       Date:  2008-09-16       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.